← Back to Search

Omega-3 Fatty Acid

Eicosapentaenoic acid monoglycerid (MAG-EPA) for Inflammation (IO3-04 Trial)

Phase 4

Waitlist Available

Led By Samuel C Fortin, PhD

Research Sponsored by SCF Pharma

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 16 weeks

Awards & highlights

IO3-04 Trial Summary

This trialis testing whether omega-3 fatty acids can help reduce risk factors for heart disease. Results suggest that a certain dose of EPA may reduce risk by 25%.

IO3-04 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 16 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~16 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Fatty acids profile analysis

Secondary outcome measures

Comparison of pre and post-dose Lipid profile.

Impact of supplementation on proportion of senescent white blood cells.

Obsevation and research of any adverse events

+2 more

IO3-04 Trial Design

1Treatment groups

Experimental Treatment

Group I: Experimental TreatmentExperimental Treatment1 Intervention

All subjects enrolled in the study will receive an identical dose of 2g/day (4 capsules of MAG-EPA) which will be taken by the subject at home. The duration of treatment should not be prolonged in the event of missed doses, that is, treatment should end on the 84th day as planned. A deviation of ± 3 days is acceptable, which means that treatment can be stopped from day 81 to day 87 of subject's participation.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

SCF PharmaLead Sponsor

6 Previous Clinical Trials

304 Total Patients Enrolled

1 Trials studying Inflammation

200 Patients Enrolled for Inflammation

Integrated Health and Social Services Centres (CISSS) de la GaspésieUNKNOWN

Integrated Health and Social Services Centres (CISSS) du Bas-St-LaurentUNKNOWN

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the administration of Eicosapentaenoic acid monoglycerid (MAG-EPA) without risk to human health?

"The safety of MAG-EPA is rated 3 due to the completion of Phase 4 trials, thereby confirming its approved status."

Answered by AI

What is the enrollment rate of participants for this medical experiment?

"Affirmative. Per the information on clinicaltrials.gov, this trial is actively recruiting patients and has been open for registration since April 21st 2021. 30 participants need to be recruited from two different medical centres before the study can begin."

Answered by AI

Are there any opportunities for volunteers to take part in the trial?

"Correct. According to clinicaltrials.gov, the trial initially posted on April 21st 2021 is currently open for recruitment, with 30 participants needed from two sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+.

2021. "Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04897893.